An Open-label study to evaluate the steady state pharmacokinetics of FDC of darunavir/cobicistat and atazanavir/cobicistat following drug intake cessation

Trial Profile

An Open-label study to evaluate the steady state pharmacokinetics of FDC of darunavir/cobicistat and atazanavir/cobicistat following drug intake cessation

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Atazanavir/cobicistat (Primary) ; Cobicistat/darunavir (Primary)
  • Indications HIV-1 infections
  • Focus Pharmacokinetics
  • Most Recent Events

    • 20 Apr 2017 New trial record
    • 12 Apr 2017 Results published in the Journal of Antimicrobial Chemotherapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top